Product, Geographic and Other Revenue Information (Tables)

9 Months Ended

Oct. 03, 2021

Schedule of Revenues by Geographic Region


The following summarizes revenues by geographic area:
	Three Months Ended					Nine Months Ended
(MILLIONS)	October 3, 2021		September 27, 2020		% Change	October 3, 2021		September 27, 2020		% Change
United States	$	7,079	$	5,425	30	$	22,269	$	15,827	41
Developed Europe	6,221		1,864		234	13,836		5,437		154
Developed Rest of World	4,498		1,065		322	8,617		2,974		190
Emerging Markets	6,296		1,923		227	12,930		5,986		116
Revenues	$	24,094	$	10,277	134	$	57,653	$	30,224	91

Schedule of Significant Product Revenues

The following provides detailed revenue information for several of our major products:


(MILLIONS)		Three Months Ended				Nine Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	Oct. 3, 2021		Sept. 27, 2020		Oct. 3, 2021		Sept. 27, 2020
TOTAL REVENUES(a)		$	24,094	$	10,277	$	57,653	$	30,224
Vaccines		$	14,583	$	1,717	$	28,711	$	4,574
Comirnaty direct sales and alliance revenues	Active immunization to prevent COVID-19	12,977		—		24,277		—
Prevnar family(b)	Pneumococcal disease	1,447		1,534		3,971		4,100
FSME/IMMUN-TicoVac	Tick-borne encephalitis disease	47		77		161		170
Nimenrix	Meningococcal ACWY disease	51		50		145		180
Trumenba	Meningococcal B disease	52		48		102		85
All other Vaccines	Various	10		8		55		39
Oncology		$	3,085	$	2,761	$	9,091	$	7,843
Ibrance	HR-positive/HER2-negative metastatic breast cancer	1,381		1,357		4,039		3,955
Xtandi alliance revenues	mCRPC, nmCRPC, mCSPC	309		266		879		741
Inlyta	Advanced RCC	256		195		742		559
Sutent	Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor	142		202		537		616
Bosulif	Philadelphia chromosome–positive chronic myelogenous leukemia	136		111		395		324
Xalkori	ALK-positive and ROS1-positive advanced NSCLC	116		122		371		409
Ruxience(c)	Non-hodgkin’s lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis (Wegener’s Granulomatosis) and microscopic polyangiitis	124		59		343		78
Retacrit(c)	Anemia	110		102		322		278
Zirabev(c)	Treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer	96		48		311		63
Lorbrena	ALK-positive metastatic NSCLC	67		55		193		142
Aromasin	Post-menopausal early and advanced breast cancer	56		35		159		107
Besponsa	Relapsed or refractory B-cell acute lymphoblastic leukemia	50		44		145		134
Braftovi	In combination with Mektovi for metastatic melanoma in patients with a BRAFV600E/K mutation and, in combination with Erbitux® (cetuximab), for the treatment of BRAFV600E-mutant mCRC after prior therapy	47		42		136		116
Bavencio alliance revenues	Locally advanced or metastatic urothelial carcinoma; metastatic Merkel cell carcinoma; immunotherapy and tyrosine kinase inhibitor combination for patients with advanced RCC	54		21		122		51
Mektovi	In combination with Braftovi for metastatic melanoma in patients with a BRAFV600E/K mutation	41		34		112		103
All other Oncology	Various	98		69		286		167
Internal Medicine		$	2,097	$	2,085	$	7,093	$	6,695
Eliquis direct sales and alliance revenues	Nonvalvular atrial fibrillation, deep vein thrombosis, pulmonary embolism	1,346		1,114		4,470		3,686
Premarin family	Symptoms of menopause	148		168		420		471
Chantix/Champix	An aid to smoking cessation treatment in adults 18 years of age or older	7		223		409		728
BMP2	Development of bone and cartilage	71		70		186		197


(MILLIONS)		Three Months Ended				Nine Months Ended
PRODUCT	PRIMARY INDICATION OR CLASS	Oct. 3, 2021		Sept. 27, 2020		Oct. 3, 2021		Sept. 27, 2020
Toviaz	Overactive bladder	56		59		174		183
Pristiq	Depression	43		40		144		124
All other Internal Medicine	Various	426		411		1,291		1,305
Hospital(a)		$	2,367	$	1,790	$	6,968	$	5,741
Sulperazon	Bacterial infections	181		143		515		432
Medrol	Anti-inflammatory glucocorticoid	109		87		320		295
Zavicefta	Bacterial infections	107		49		306		143
EpiPen	Epinephrine injection used in treatment of life-threatening allergic reactions	78		75		225		234
Fragmin	Treatment/prevention of venous thromboembolism	74		60		223		178
Vfend	Fungal infections	51		52		204		201
Zithromax	Bacterial infections	66		25		198		218
Tygacil	Bacterial infections	56		33		153		115
Precedex	Sedation agent in surgery or intensive care	50		55		147		211
Zyvox	Bacterial infections	41		51		144		176
IVIg Products(d)	Various	99		88		311		271
Pfizer CentreOne(e)	Various	521		242		1,348		618
All other Anti-infectives	Various	355		301		1,081		936
All other Hospital	Various	577		529		1,794		1,713
Inflammation & Immunology (I&I)		$	1,094	$	1,173	$	3,200	$	3,299
Xeljanz	RA, PsA, UC, active polyarticular course juvenile idiopathic arthritis	610		654		1,734		1,741
Enbrel (Outside the U.S. and Canada)	RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis	283		321		888		1,005
Inflectra/Remsima(c)	Crohn’s disease, pediatric Crohn’s disease, UC, pediatric UC, RA in combination with methotrexate, ankylosing spondylitis, PsA and plaque psoriasis	172		162		485		471
All other I&I	Various	28		35		93		83
Rare Disease		$	869	$	752	$	2,588	$	2,071
Vyndaqel/Vyndamax	ATTR-cardiomyopathy and polyneuropathy	501		351		1,454		859
BeneFIX	Hemophilia B	104		107		328		337
Genotropin	Replacement of human growth hormone	95		107		284		316
Refacto AF/Xyntha	Hemophilia A	69		92		235		272
Somavert	Acromegaly	70		67		203		198
All other Rare Disease	Various	30		27		84		89
Total Alliance revenues		$	2,068	$	1,250	$	5,718	$	4,036
Total Biosimilars(c)		$	575	$	424	$	1,663	$	1,001
Total Sterile Injectable Pharmaceuticals(f)		$	1,443	$	1,192	$	4,306	$	3,826

(a)On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See Note 1A. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.

(b)Prevnar family include revenues from Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20 (adult).

(c)Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima, Ruxience, Retacrit and Zirabev.

(d)Intravenous immunoglobulin (IVIg) products include the revenues from Panzyga, Octagam and Cutaquig.

(e)Pfizer CentreOne includes revenues from our contract manufacturing, including certain Comirnaty-related manufacturing activities performed on behalf of BioNTech ($187 million and $274 million for the third quarter and the first nine months of 2021, respectively), and active pharmaceutical ingredient sales operation, as well as revenues related to our manufacturing and supply agreements with former legacy Pfizer businesses/partnerships, including but not limited to, transitional manufacturing and supply agreements with Viatris following the spin-off of the Upjohn Business.

(f)Total Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital therapeutic area, including anti-infective sterile injectable pharmaceuticals.